Personalis (NASDAQ:PSNL) Stock Rating Lowered by Wall Street Zen

Key Points

• Wall Street Zen downgraded Personalis from hold to sell, adding a bearish note to the stock’s recent analyst coverage.
• Despite the downgrade, broader analyst sentiment remains mixed-to-positive: the stock has five Buy ratings, one Hold, and one Sell, with an average Moderate Buy rating and a $11.50 average price target.
• Personalis also reported a Q1 EPS miss, posting ($0.29) per share versus expectations of ($0.23), even though quarterly revenue of $15.47 million came in above estimates.

Personalis (NASDAQ:PSNL - Get Free Report) was downgraded by Wall Street Zen from a "hold" rating to a "sell" rating in a research report issued on Saturday.

A number of other equities research analysts have also recently commented on PSNL. Guggenheim raised their target price on shares of Personalis from $12.00 to $13.00 and gave the stock a "buy" rating in a research note on Monday, January 26th. Morgan Stanley decreased their target price on shares of Personalis from $11.00 to $10.00 and set an "equal weight" rating on the stock in a research note on Thursday, March 5th. Weiss Ratings restated a "sell (d-)" rating on shares of Personalis in a research note on Tuesday, April 21st. Needham & Company LLC raised their target price on shares of Personalis from $10.00 to $12.00 and gave the stock a "buy" rating in a research note on Friday, February 27th. Finally, BTIG Research raised their target price on shares of Personalis from $12.00 to $13.00 and gave the stock a "buy" rating in a research note on Wednesday, February 11th. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $11.50.

Personalis Trading Down 0.2%

NASDAQ PSNL opened at $5.98 on Friday. Personalis has a 12 month low of $3.84 and a 12 month high of $11.50. The stock has a market cap of $625.99 million, a price-to-earnings ratio of -5.86 and a beta of 1.96. The company's 50 day moving average is $6.93 and its two-hundred day moving average is $8.23.

Personalis (NASDAQ:PSNL - Get Free Report) last released its earnings results on Thursday, May 7th. The company reported ($0.29) EPS for the quarter, missing analysts' consensus estimates of ($0.23) by ($0.06). Personalis had a negative return on equity of 45.98% and a negative net margin of 148.11%.The firm had revenue of $15.47 million for the quarter, compared to the consensus estimate of $14.49 million. Sell-side analysts forecast that Personalis will post -1.01 EPS for the current year.

Institutional Investors Weigh In On Personalis

Several institutional investors and hedge funds have recently modified their holdings of PSNL. Caitong International Asset Management Co. Ltd raised its position in shares of Personalis by 76.1% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,423 shares of the company's stock valued at $27,000 after buying an additional 1,479 shares during the last quarter. Legal & General Group Plc bought a new stake in shares of Personalis during the second quarter valued at approximately $30,000. International Assets Investment Management LLC bought a new stake in shares of Personalis during the fourth quarter valued at approximately $31,000. BNP Paribas Financial Markets raised its position in shares of Personalis by 406.4% during the second quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company's stock valued at $42,000 after buying an additional 5,177 shares during the last quarter. Finally, Focus Partners Wealth bought a new stake in shares of Personalis during the first quarter valued at approximately $47,000. Institutional investors own 61.91% of the company's stock.

Personalis Company Profile

Personalis, Inc NASDAQ: PSNL is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company's core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.